Moon Jellyfish Stings

formed. The exanthema and the eosinophilia decreased gradually until normalization was achieved on day 16. On day 19, vemurafenib therapy was discontinued, and within 7 days thereafter, the fever had improved, and the electrolyte profile had normalized. Tumor assessment showed a major tumoral response. On day 29, vemurafenib treatment was restarted at half dose, leading within 21 days (day 50) to a relapse of hypokalemia and hypouricemia with acute urinary loss but without relapse of fever, exanthema, or eosinophilia. Vemurafenib treatment was then definitively stopped, followed by normalization of electrolytic findings within 5 days. At that time, treatment with dabrafenib, another BRAF inhibitor, was started. At last follow-up 5 months later, no adverse event had occurred.